Mineralys Therapeutics, Inc.

NASDAQ:MLYS

Biotechnology

Healthcare
$13.78 +1.49%

+$0.37 today

Market cap
$1.22B
Beta
0.56
P/E (TTM)
-13.9
EPS (TTM)
-$1.83
52W Low $12.59High $47.65

Volume 1.39M

Average 1.48M

MLYS Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Mineralys Therapeutics, Inc.NASDAQ: MLYS

Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026

Depreciation & amortization declines year over year

Q2 FY2026 depreciation & amortization of $5K fell 68.8% year over year, behind the -31.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 16.7% from the prior quarter.

Context

  • Depreciation & amortization increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -68.8% toward the trailing-twelve-month pace of -31.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$5K-16.7% QoQ
Last fiscal yearDec 2025
$59K+37.2% YoY
LTMJun 2026
$39K-31.6% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-68.8%——
1 year+37.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
59K USD
Year-over-year change
+37.2%

Depreciation & Amortization vs competitors

How MLYS compares with its peers on the latest reported figures

  • MLYS's LTM Jun 2026 depreciation & amortization of $39K is the lowest of the 7 companies compared; the peer median is $592K.
  • Its year-over-year change of -31.6% is the lowest of 7, against a peer median of +3.9%.
MLYS Competitors Peer median
Depreciation & Amortization for MLYS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TVTXTravere Therapeutics, Inc.LTM Sep 2026$47.58M -13.0%+43.1%7.3%
MAZEMaze Therapeutics, Inc.LTM Mar 2026$2.16M -28.6%-14.3%10.8%
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026$648K +144.5%+52.6%—
VERAVera Therapeutics, Inc.LTM Jun 2026$536K +89.4%——
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$334K +5.4%+13.8%1.0%
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$43K +2.4%+19.8%—
MLYSMineralys Therapeutics, Inc.LTM Jun 2026$39K -31.6%——
Peer median (excluding MLYS) $592K+3.9%+19.8%7.3%

Competitors are the stored peer set for MLYS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development16.31M26.25M70.36M168.58M132.01M
Selling, General & Admin2.42M5.23M14.3M23.82M38.6M
Operating Expenses18.73M31.48M84.66M192.4M170.6M
Depreciation & Amortization00043K59K
EBITDA(19.38M)(28.12M)(71.9M)(177.77M)(154.59M)
EBITDA Margin—————
Operating Income(18.73M)(31.48M)(84.66M)(192.4M)(170.6M)
Operating Margin—————
Interest Income01.68M12.76M14.59M15.95M
Interest Expense27K1.68M000
Other Income / Expenses(683K)1.68M12.76M14.59M15.95M
Income Before Tax(19.41M)(29.8M)(71.9M)(177.81M)(154.65M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(19.41M)(29.8M)(71.9M)(177.81M)(154.65M)
Net Margin—————
EPS (Basic)(3.89)(5.77)(1.99)(3.66)(2.29)
EPS (Diluted)(3.89)(5.77)(1.99)(3.66)(2.29)
Weighted Avg Shares4.98M5.17M36.19M48.54M67.66M
Weighted Avg Shares (Diluted)4.98M5.17M36.19M48.54M67.66M

Mineralys Therapeutics, Inc.

NASDAQ:MLYS

Intrinsic Alpha fair value

Locked

Current Price

$13.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.